Should a 46-year-old woman taking semaglutide (Wegovy) 7.2 mg for weight loss continue the medication despite experiencing diffuse cold‑triggered prickly/burning paresthesias after injections, given that there is no sensory loss?

Continue Wegovy with Close Monitoring and Dose Adjustment Consideration

The prickly/burning paresthesias are likely related to Wegovy (semaglutide), but continuation is reasonable given the absence of sensory loss, effective weight loss, and manageable symptoms—provided you implement close monitoring and consider dose reduction if symptoms worsen. 1

Understanding the Symptom Pattern

The cold-triggered prickly/burning paresthesias that recur after injections and improve later in the dosing interval suggest a dose-related phenomenon. This temporal pattern—worsening post-injection and improving as drug levels decline—is characteristic of medication-related effects rather than progressive neuropathy.

Key Clinical Distinctions

• No sensory loss present: This is the critical safety threshold. The absence of objective sensory deficits distinguishes tolerable side effects from concerning neurological complications
• Symptom fluctuation with dosing: The improvement later in the dosing interval strongly implicates the medication
• Manageable severity: Patient reports symptoms remain tolerable

Evidence-Based Management Strategy

Immediate Actions

Continue current dose (7.2 mg) while implementing enhanced monitoring:

• Weekly symptom diary tracking: severity (0-10 scale), timing relative to injection, any progression to numbness
• Immediate discontinuation criteria: development of sensory loss, progressive worsening despite dose adjustment, or intolerable symptoms
• Consider switching injection sites systematically to rule out local injection-related causes

Dose Optimization Approach

The 7.2 mg dose mentioned in your note exceeds the FDA-approved maximum of 2.4 mg weekly for Wegovy 1. This is crucial:

• Standard FDA-approved dosing: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maximum maintenance dose) 1
• Higher investigational doses (7.2 mg) are currently in Phase 3 trials for obesity with type 2 diabetes but are not yet approved 2

If the patient is truly on 7.2 mg weekly, this represents off-label dosing and may explain the paresthesias. Consider:

1. Verify the actual prescribed dose (possible documentation error?)
2. If truly on 7.2 mg: Reduce to FDA-approved maximum of 2.4 mg weekly, which may resolve symptoms while maintaining efficacy
3. If on 2.4 mg or less: The symptoms may represent an idiosyncratic reaction requiring closer monitoring

GLP-1 RA Side Effect Profile Context

The most common adverse effects of semaglutide are gastrointestinal (nausea, vomiting, diarrhea, constipation) occurring in 40-50% of patients 3, 4, 5. Paresthesias are not listed among the common or established adverse effects in major guidelines or FDA labeling 1, 3, 2.

However, rare neurological symptoms have been reported in post-marketing surveillance, and the temporal relationship here is suggestive.

Risk-Benefit Analysis for This Patient

Benefits of Continuation

• Effective weight loss on current regimen
• Cardiovascular protection: Semaglutide 2.4 mg reduces MACE by 20% in patients with established CVD 2, 4
• Metabolic improvements: Addressing her dyslipidemia (LDL 179), Stage 2 CKD (eGFR 86), and multiple comorbidities
• Renal protection: GLP-1 RAs prevent decline in renal function 2

Risks of Continuation

• Potential progression to sensory neuropathy: Though currently absent
• Unknown etiology: Paresthesias not well-characterized in literature for semaglutide
• Possible vitamin B12 deficiency contribution: She's on levothyroxine; if also on metformin (not mentioned but common), B12 deficiency can cause paresthesias 6, 7

Risks of Discontinuation

• Weight regain: Studies show 11.6% weight regain after 52 weeks post-cessation 4
• Loss of cardiometabolic benefits: Increased cardiovascular risk, worsening dyslipidemia
• Psychological impact: Frustration with treatment interruption

Specific Monitoring Protocol

Weekly for first month, then monthly:

• Symptom severity score (0-10)
• Presence/absence of objective sensory deficits (light touch, pinprick, vibration, proprioception)
• Distribution pattern (distal vs. proximal, symmetric vs. asymmetric)
• Impact on quality of life and daily function

Laboratory evaluation:

• Vitamin B12 level: Deficiency causes paresthesias and is common with metformin use 6, 7
• TSH and free T4: Ensure thyroid optimization (current TSH 0.522 is appropriate)
• HbA1c: Rule out undiagnosed diabetes causing neuropathy
• Comprehensive metabolic panel: Assess electrolytes, renal function

Alternative Considerations if Symptoms Progress

Dose Reduction Strategy

If symptoms worsen despite monitoring:

• Reduce to 1.7 mg weekly (one step down from 2.4 mg maximum) 1
• Reassess after 4 weeks
• Many patients achieve adequate weight loss at submaximal doses 3

Alternative GLP-1 RA Options

If dose reduction inadequate:

• Liraglutide 3.0 mg daily: Different pharmacokinetic profile (shorter half-life: 13 hours vs. 7 days for semaglutide) may reduce sustained exposure-related effects 2, 4
• Tirzepatide: Dual GIP/GLP-1 RA with potentially different side effect profile 2

Non-GLP-1 RA Alternatives

If all GLP-1 RAs problematic:

• Phentermine/topiramate ER: Effective but requires cardiovascular screening given her CKD 3, 7
• Naltrexone/bupropion: Less effective but may be tolerated 7

Critical Safety Thresholds for Immediate Discontinuation

Stop Wegovy immediately and notify office if:

• Development of sensory loss (numbness, inability to feel light touch)
• Progressive worsening of paresthesias despite dose adjustment
• Bilateral symmetric distal paresthesias suggesting peripheral neuropathy
• Motor weakness or gait disturbance
• Intolerable symptoms affecting quality of life

Common Pitfalls to Avoid

1. Dismissing symptoms as "just side effects": While GI effects are expected, neurological symptoms warrant careful evaluation
2. Failing to verify actual prescribed dose: The 7.2 mg dose mentioned exceeds FDA approval
3. Not checking vitamin B12: Simple, treatable cause of paresthesias often overlooked
4. Premature discontinuation: Losing significant cardiometabolic benefits without adequate trial of dose adjustment
5. Ignoring the temporal pattern: The post-injection worsening/interval improvement strongly suggests medication relationship

Bottom Line

Continue Wegovy with enhanced monitoring, verify the actual prescribed dose (7.2 mg exceeds FDA approval), check vitamin B12 levels, and establish clear discontinuation criteria. The absence of sensory loss and manageable symptoms support continuation, but the unusual nature of these paresthesias requires vigilance. If truly on 7.2 mg, reduction to the FDA-approved maximum of 2.4 mg may resolve symptoms while maintaining efficacy. The substantial benefits for her multiple comorbidities (obesity, dyslipidemia, CKD, cardiovascular risk) justify a cautious continuation approach with structured monitoring rather than immediate discontinuation.